After two flops, Roche and Exelixis post early PhIII win for Tecentriq/Cabometyx combo — but will wait for OS data

Amber Tong

Roche and Exelixis have finally notched a Phase III win with the combination of Tecentriq and Cabometyx, clearing the progression-free survival bar in metastatic castration …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After two flops, Roche and Exelixis post early PhIII win for Tecentriq/Cabometyx combo — but will wait for OS data

Amber Tong

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter two flops, Roche and Ex­elix­is post ear­ly PhI­II win for Tecen­triq/Cabome­tyx com­bo — but will wait for OS da­ta

Amber Tong

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA says Ozem­pic, We­govy short­age is over

Kevin Tang's Con­cen­tra tries to dis­rupt pro­posed Ace­lyrin-Alu­mis merg­er

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Mer­ck KGaA tees up changes to lead­er­ship team; Ex-CVS Health CEO joins Ther­mo Fish­er’s board

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

After two flops, Roche and Exelixis post early PhIII win for Tecentriq/Cabometyx combo — but will wait for OS data

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA says Ozempic, Wegovy shortage is over

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence